Received May 25, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNP | MENINGOCOCCAL CONJUGATE (PENMENVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Administration of only the liquid component; Administration of only the liquid component; This non-serious case was reported by a other health professional via sales rep and described the occurrence of inappropriate dose of vaccine administered in a patient who received Men ABCWY NVS (Penmenvy) for prophylaxis. On an unknown date, the patient received Penmenvy. On an unknown date, an unknown time after receiving Penmenvy, the patient experienced inappropriate dose of vaccine administered (Verbatim: Administration of only the liquid component) and inappropriate preparation of medication (Verbatim: Administration of only the liquid component). The outcome of the inappropriate dose of vaccine administered and inappropriate preparation of medication were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date 19-MAY-2026 The patient received Men B component of Penmenvy but it was not reconstituted with the lyophilized Men ACWY component. The reporter wanted to know what was the best course of action for the patient to receive the Men ACWY component. The batch number was not provided upon follow- up with the reporter.